Aspira Women’s Health Secures New Agreement with Anthem Blue Cross, CA

Texas-based diagnostic tools company, Aspira Women’s Health (Nasdaq: AWH), has entered into a new agreement with Anthem Blue Cross in California for reimbursement coverage of the Company’s OvaSuiteSM portfolio of risk assessment tests effective June 1, 2024. Aspira’s OvaWatch® and Ova1Plus® provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year.

Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.

Commenting on the agreement, Torsten Hombeck, Chief Financial Officer of Aspira, said, “We are very pleased to add Anthem Blue Cross to our list of payers providing coverage for our OvaSuite portfolio, which provides a clear benefit to physicians in their clinical assessment of women with adnexal masses, This is the first in a series of anticipated agreements with Anthem affiliated members following our successful completion of its credentialing process in March. Our strategic focus on payer adoption continues to gather momentum.”

Anthem and its affiliated companies serve more than 118 million people, including more than 45 million in its family of health plans.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women planned for surgery.